We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata & TESARO Win CARE 'Clinical Partnership' Award
Read MoreHide Full Article
Headquartered in NY, Medidata Solutions Inc. , a worldwide producer of cloud-based solutions for life sciences, recently announced the receipt of the ‘Clinical Partnership of the Year’ award at the second annual Clinical and Research Excellence (CARE) Awards, courtesy of its ‘unique technology collaboration’ with TESARO.
Notably, TESARO has been working closely with Medidata since 2013, especially on features like the Medidata Balance – a platform that enhances the clinical trial supply management of Medidata. Medidata Balance is a fully configurable randomization and trial supply management (RTSM) solution that leverages on the company’s flagship Medidata Rave platform.
TESARO and Medidata’s highly exclusive cross-functional product development process on building the software blueprints of the Medidata Balance has largely supported the win. This eased out bottlenecks pertaining to drug supply during trials, reduced the cost on drug labeling and paved way for sharing of inventories between companies.
Per management, the partnership was a ‘win-win project’ for both the companies. Furthermore, Medidata and TESARO managed to put a check on clinical research (R&D) costs which are borne by the entire medical fraternity, especially clinical trial companies.
Medidata has been a gaining prominence of late, courtesy of its broad-based product portfolio which includes Medidata Rave, Medidata Coder, Image Management, Risk-Based Monitoring, Medidata CTMS and Medidata Patient Cloud. Notably, Medidata Cloud addressed 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet development needs.
Stock Price Trend
Medidata has had an impressive run on the bourse in the past one year. The stock returned almost 52.8%, comparing favorably with the Zacks classified Medical Information Systems sub-industry’s loss of 7.8%. Furthermore, the stock’s return is well ahead of the S&P 500’s 13.2% over the same time frame.
Coming to the estimate revision trend, two estimates moved north in the last two months compared to no movement in the opposite direction for the full year. As a result, current year estimates inched up 7.1% to 75 cents per share over the same time frame.
The bullish analyst sentiments justify the stock’s Zacks Rank #2 (Buy).
Our Take
The global clinical trial supplies market has solid prospects as it is forecast to reach a worth of $1,274.3 million by 2020, growing at a CAGR of 7.1% (Markets And Markets). This highlights the potential of Medidata’s Clinical Cloud platform for clinical trial supplies in the coming quarters.
Also, a long-term expected earnings growth rate of 21.67% and a projected sales growth of 18.95% instill our confidence on the stock.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 86.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock represents a stellar one-year return of 20.02%.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock posted a positive earnings surprise of 1.6% in the last reported quarter.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medidata & TESARO Win CARE 'Clinical Partnership' Award
Headquartered in NY, Medidata Solutions Inc. , a worldwide producer of cloud-based solutions for life sciences, recently announced the receipt of the ‘Clinical Partnership of the Year’ award at the second annual Clinical and Research Excellence (CARE) Awards, courtesy of its ‘unique technology collaboration’ with TESARO.
Notably, TESARO has been working closely with Medidata since 2013, especially on features like the Medidata Balance – a platform that enhances the clinical trial supply management of Medidata. Medidata Balance is a fully configurable randomization and trial supply management (RTSM) solution that leverages on the company’s flagship Medidata Rave platform.
TESARO and Medidata’s highly exclusive cross-functional product development process on building the software blueprints of the Medidata Balance has largely supported the win. This eased out bottlenecks pertaining to drug supply during trials, reduced the cost on drug labeling and paved way for sharing of inventories between companies.
Per management, the partnership was a ‘win-win project’ for both the companies. Furthermore, Medidata and TESARO managed to put a check on clinical research (R&D) costs which are borne by the entire medical fraternity, especially clinical trial companies.
Medidata Solutions, Inc. Price
Medidata Solutions, Inc. Price | Medidata Solutions, Inc. Quote
Medidata has been a gaining prominence of late, courtesy of its broad-based product portfolio which includes Medidata Rave, Medidata Coder, Image Management, Risk-Based Monitoring, Medidata CTMS and Medidata Patient Cloud. Notably, Medidata Cloud addressed 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet development needs.
Stock Price Trend
Medidata has had an impressive run on the bourse in the past one year. The stock returned almost 52.8%, comparing favorably with the Zacks classified Medical Information Systems sub-industry’s loss of 7.8%. Furthermore, the stock’s return is well ahead of the S&P 500’s 13.2% over the same time frame.
Coming to the estimate revision trend, two estimates moved north in the last two months compared to no movement in the opposite direction for the full year. As a result, current year estimates inched up 7.1% to 75 cents per share over the same time frame.
The bullish analyst sentiments justify the stock’s Zacks Rank #2 (Buy).
Our Take
The global clinical trial supplies market has solid prospects as it is forecast to reach a worth of $1,274.3 million by 2020, growing at a CAGR of 7.1% (Markets And Markets). This highlights the potential of Medidata’s Clinical Cloud platform for clinical trial supplies in the coming quarters.
Also, a long-term expected earnings growth rate of 21.67% and a projected sales growth of 18.95% instill our confidence on the stock.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Fluidigm Corporation . Notably, Inogen and Hologic sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 86.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock represents a stellar one-year return of 20.02%.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock posted a positive earnings surprise of 1.6% in the last reported quarter.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>